Marine Fish Bone Peptides Counteract Angiotensin II-Mediated Endothelial Dysfunction via AKT/eNOS and Nrf2 Activation

Study Background and Research Question

Vascular endothelial cell injury is a critical event in the development of cardiovascular diseases, notably hypertension and atherosclerosis. The endogenous octapeptide Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is a potent vasopressor and an established model agonist for inducing oxidative stress, inflammation, and apoptosis in vascular endothelial cells. Elevated Angiotensin II levels drive the pathogenesis of hypertension and promote endothelial dysfunction by increasing reactive oxygen species (ROS), modulating endothelin-1 (ET-1), and impairing nitric oxide (NO) signaling. Despite extensive research into pharmacological intervention, there remains a need to identify protective agents that can mitigate Angiotensin II-induced vascular damage, especially from underexplored natural sources.

The reference study (Shao et al., ACS Omega, 2023) investigates whether bioactive peptides isolated from Harpadon nehereus (Bombay duck) bone can prevent or reverse Angiotensin II-induced injury and dysfunction in human umbilical vein endothelial cells (HUVECs). Specifically, the research aims to characterize the molecular mechanisms underpinning the protective effects of the peptides KA-8 (KLHDEEVA) and PG-7 (PSRILYG), focusing on their impact on oxidative stress and endothelial signaling pathways.

Key Innovation from the Reference Study

The central innovation of this work is the identification and mechanistic validation of two marine-derived peptides that significantly counteract the deleterious effects of Angiotensin II on endothelial cells. Notably, the peptide PG-7 exhibits pronounced upregulation of the Nrf2 antioxidant pathway and the AKT/eNOS signaling axis, both critical for cellular defense against oxidative and functional vascular injury. These findings expand the utility of underused fish processing byproducts, providing a sustainable source of bioactive compounds with translational potential for cardiovascular disease mitigation. Additionally, the study offers new insights into the modulation of vascular function by natural peptides, with direct implications for hypertension mechanism study and vascular smooth muscle cell hypertrophy research.

Methods and Experimental Design Insights

The authors employed a robust in vitro model using HUVECs to simulate Angiotensin II-induced endothelial dysfunction. Angiotensin II was sourced from APExBIO (see product information) and administered to HUVECs to induce oxidative damage and dysfunction, mimicking hypertensive vascular stress. The two peptides, KA-8 and PG-7, were previously isolated and characterized from the hydrolysate of Harpadon nehereus bone collagen.

Key experimental endpoints included:

• Measurement of intracellular ROS levels to assess oxidative stress burden.
• Quantification of antioxidant enzyme activities (e.g., NQO1, HO-1) and detection of Nrf2 nuclear translocation.
• Evaluation of endothelial dysfunction markers, such as ET-1 expression and NO production.
• Analysis of PI3K, AKT, and eNOS phosphorylation as indicators of pro-survival and vasoprotective signaling.
• Peptide-ACE binding affinity and inhibition assays to assess potential antihypertensive activity.

The study design allows for the dissection of both antioxidant and endothelial function pathways in response to peptide treatment, providing mechanistic clarity that extends beyond simple cytoprotection.

Protocol Parameters

• Angiotensin II treatment: HUVECs exposed to 1 μM Ang II for 24 hours to induce oxidative stress and dysfunction (reference study).
• Peptide pretreatment: Cells pretreated with KA-8 (100 μM) or PG-7 (100 μM) for 2 hours prior to Ang II challenge.
• Antioxidant and signaling assays: ROS, Nrf2, NQO1, HO-1, ET-1, NO, p-AKT, and p-eNOS measured by fluorescence, ELISA, and Western blot.
• ACE inhibition: In vitro ACE activity assay using peptide concentrations ranging up to 1000 μM to determine IC50 values.

Core Findings and Why They Matter

The reference study provides several lines of evidence supporting the protective efficacy of KA-8 and, more potently, PG-7 against Angiotensin II-mediated endothelial injury:

• Reduction in ROS and ET-1: Both peptides significantly lowered ROS accumulation and ET-1 expression in HUVECs challenged with Angiotensin II, indicating attenuation of oxidative stress and vasoconstrictive signaling.
• Activation of Nrf2 Antioxidant Pathway: PG-7, in particular, increased nuclear translocation of Nrf2 and upregulated downstream antioxidant enzymes (NQO1, HO-1), enhancing the cellular oxidative defense response.
• Restoration of AKT/eNOS Signaling: PG-7 restored phosphorylation of PI3K, AKT, and eNOS, leading to improved NO bioavailability and endothelial function. This pathway is known to mediate survival and vasodilation in endothelial cells.
• Inhibition of ACE Activity: PG-7 demonstrated higher binding affinity to ACE and stronger ACE inhibitory activity compared to KA-8, suggesting direct antihypertensive potential.

These mechanistic findings suggest that marine-derived peptides can address both the oxidative and functional sequelae of Angiotensin II exposure, potentially informing novel interventions for hypertension and vascular remodeling (Shao et al., 2023).

Comparison with Existing Internal Articles

The reference study’s mechanistic focus on Angiotensin II-induced oxidative stress and endothelial dysfunction complements several recent reviews of Angiotensin II’s role in cardiovascular disease models. For example, APExBIO’s Angiotensin II workflow guide details practical protocols for inducing vascular smooth muscle cell hypertrophy and abdominal aortic aneurysm, paralleling the use of Angiotensin II as an experimental trigger in the present study. Similarly, a mechanistic benchmark review discusses Angiotensin II’s GPCR agonist activity and its downstream signaling, reinforcing the relevance of the AKT/eNOS and antioxidant pathways targeted by PG-7.

The present research adds depth to these established models by demonstrating that specific natural peptides can reverse Angiotensin II-induced injury, not only by inhibiting ROS but also by modulating key survival and vasodilatory pathways. This dual mechanism differentiates the peptide approach from traditional pharmacological blockade and could inform future cardiovascular remodeling investigations.

Limitations and Transferability

While the in vitro findings are robust and mechanistically detailed, several limitations must be acknowledged. The experiments were conducted exclusively in HUVECs, and thus the efficacy and bioavailability of KA-8 and PG-7 in vivo remain untested. The concentrations required for significant protection (100 μM) may not be readily achievable in physiological settings without further formulation or delivery optimization. Furthermore, the study does not address long-term effects, peptide stability, or potential off-target actions.

Despite these limitations, the data provide a foundation for translational studies in animal models of hypertension and vascular injury, where Angiotensin II infusion is a standard approach. The selective upregulation of Nrf2 and AKT/eNOS by PG-7, along with its ACE inhibitory effects, supports further investigation into its potential as an adjunct or alternative to existing antihypertensive therapies.

Research Support Resources

Researchers aiming to model Angiotensin II-induced vascular injury, hypertension, or endothelial dysfunction can utilize high-purity Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) available from APExBIO (SKU A1042). This reagent supports reproducible induction of oxidative stress and vascular remodeling in cell and animal models, with established protocols for dose and duration. For detailed workflow guidance on using Angiotensin II in vascular smooth muscle cell hypertrophy research or abdominal aortic aneurysm models, consult related internal articles and the referenced product documentation.

Further research into natural peptide modulators, such as those identified from Harpadon nehereus bone, may yield new avenues for therapeutic development in the context of cardiovascular disease.